低级别浆液性卵巢癌一线激素维持治疗的系统综述
研究间激素方案、剂量和人群异质性显著,仅一项回顾性研究显示无进展生存改善,另两项未显示显著获益,证据有限。
要点
- 低级别浆液性卵巢癌对传统化疗反应差,一线减瘤术后激素维持治疗证据有限。
- 纳入4项队列研究共558例,其中127例接受激素维持治疗,研究间异质性显著。
- 仅一项回顾性研究显示无进展生存改善,另两项未显示显著获益,需前瞻性随机试验验证。
核心结论
- 低级别浆液性卵巢癌治疗仍具挑战,激素维持治疗获益证据有限,需设计良好的前瞻性随机试验确认。
研究设计与样本
- 纳入描述低级别浆液性卵巢癌患者减瘤术后(伴或不伴化疗)一线激素维持治疗的文献,最终纳入4项队列研究,共558例患者,其中127例接受激素维持治疗。
主要发现
- 文献检索共识别14,799条记录,4项队列研究符合纳入标准。
- 研究间激素维持治疗方案、剂量和研究人群存在显著异质性,导致治疗结局多样。
- 一项回顾性研究显示激素维持治疗后无进展生存改善,另两项研究未显示显著改善。
临床怎么用
- 低级别浆液性卵巢癌一线减瘤术后激素维持治疗可作为个体化讨论选项,但需告知证据有限且研究间异质性大。
局限性
- 文献数据有限,限制结果外推。
- 纳入研究均为回顾性队列,研究间激素方案、剂量和人群异质性显著。
- 缺乏前瞻性随机试验证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Low-grade serous ovarian cancer (LGSOC) is a rare form of ovarian cancer that accounts for 5-10% of epithelial ovarian cancers. LGSOCs are difficult to treat as they respond poorly to traditional chemotherapy treatments. This systematic review aims to appraise the literature describing the efficacy of hormone maintenance therapy (HMT) in patients with LGSOC given after cytoreductive surgery. METHODS: Medline, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews were searched from inception to November 2020. No language restrictions were applied. Publications describing HMT in the primary setting following cytoreductive surgery with or without chemotherapy in women with LGSOC were included. Publications describing HMT in recurrence, non-LGSOC carcinomas, and in-vitro or animal studies were excluded along with case reports, case series, and conference proceedings. We summarized oncologic outcomes, HMT used, and hormone receptor status where reported. Studies were assessed for risk of bias and quality of evidence. RESULTS: The literature search identified 14,799 records. Four cohort studies met eligibility criteria. A total of 558 patients were included, of which 127 were treated with HMT. There was significant heterogeneity between studies demonstrated by differences in HMT regimens used, dosing, and study population, leading to various outcomes following treatment with HMT. CONCLUSIONS: Treatment of LGSOC remains a challenge. One retrospective study demonstrated improved progression-free survival following HMT for LGSOC, while two others failed to show significant improvements. However, there is limited data available in the literature which restricts the generalizability of these results. Therefore, well-designed, prospective, and randomized trials are needed to confirm the benefit of HMT in patients with this rare subgroup of ovarian cancer.
引用
- Lazurko C, Clark M, Pulman K, et al. Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review. Gynecol Oncol. 2021. PMID: 34325937. doi:10.1016/j.ygyno.2021.07.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。